Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
238.3 USD | +1.89% | +1.79% | +8.35% |
23/04 | United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing | MT |
23/04 | United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 9.76 for the current year and 9.5 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.35% | 11B | B+ | ||
+1.77% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.24% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.44% | 25.49B | B- | ||
-23.01% | 18.12B | B | ||
+30.56% | 12.24B | C+ | ||
-1.82% | 11.76B | C+ | ||
-16.39% | 10.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UTHR Stock
- Ratings United Therapeutics Corporation